Life sciences strength will drive UK pharma sector growth
March 30, 2016Sales and Marketing
The UK pharmaceutical market is set to grow from $28.8 billion in 2015 to approximately $43 billion by 2020, at …
US lawmakers demand price cut for Astellas, Medivation’s prostate cancer drug Xtandi
March 30, 2016Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Japan, Medivation, US FDA, Xtandi, drug price
US lawmakers have asked the National Institutes of Health and the Department of Health and Human Services to ‘use its …
Shire wins v Allergan in Lialda patent case
March 30, 2016Research and Development, Sales and Marketing Allergan, Shire, lialda
A US district court has ruled that Shire’s patent for ulcerative colitis drug Lialda is valid through 2020, leaving Allergan …
Keryx Biopharmaceuticals announces positive Phase III study results for anaemia treatment
March 30, 2016Research and Development CKD, anaemia, chronic kidney disease, clinical trial, dialysis, keryx, keryx biopharmaceuticals, kidney, phase 3, phase III
Keryx Biopharmaceuticals (NASDAQ: KERX) has announced positive top-line results for its Phase III study of ferric citrate for the treatment …
Sun Pharma forays into Japan with $293 million product buy from Novartis
March 30, 2016Manufacturing and Production, Research and Development, Sales and Marketing Japan, M&A, MA, Novartis, Sun Pharma, generics
Shares of Sun Pharma (BOM: 524715), the largest Indian drug maker rose over 2% Wednesday as the company announced the …
Eisai announces agreement to set up new gastrointestinal speciality company
March 30, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ajinomoto, Eisai, absorption, acquisition, ea pharma, gastrointestinal, merger, speciality
Eisai (TYO: 4523) and Ajinomoto Co. (TYO: 2802) have announced an agreement to establish a new gastrointestinal speciality pharmaceutical company, …
FDA says positives outweigh risks on Acadia’s Parkinson’s psychosis drug
March 30, 2016Research and Development, Sales and Marketing FDA, Parkinson's, Parkinsons, acadia, nuplazid, pimavanserin, psychosis
Acadia Pharmaceuticals (NASDAQ: ACAD) has announced a positive result from the US Food and Drug Administration (FDA) concerning Nuplazid (pimavanserin) …
Biosimilars could save healthcare systems $100bn by 2020
March 30, 2016Research and Development, Sales and Marketing biosimilars
The growth of the market for biosimilar drugs has the potential to save EU and US healthcare systems up to …
Lupin drops on FDA observations; company reassures of no disruption at facility
March 29, 2016Business Services, Manufacturing and Production, Sales and Marketing Lupin, US FDA, regulation
Shares of India’s Lupin dropped over 14% Tuesday following news the US Food and Drug Administration (FDA) has made observations …
GSK’s Nucala gets regulatory approval in Japan to treat bronchial asthma
March 29, 2016Manufacturing and Production, Research and Development GlaxoSmithKline, Japan, Nucala, US FDA, bronchial asthma
GlaxoSmithKline (LSE: GSK) on Tuesday said the Japanese regulators have approved its drug to treat bronchial asthma. The Japanese Ministry …
Valeant’s outgoing CEO subpoenaed by US congressional committee
March 29, 2016Medical Communications, Research and Development Drug pricing, Michael Pearson, US, Valeant, committee, pearson, pharma, price hikes, senate aging committee, subpoena, subpoenaed
The US Senate Aging Committee has announced the issuing of a subpoena to the outgoing CEO of Valeant Pharmaceuticals, Michael …
TREND: Rare disease, cancer drugs will drive pharma M&A’s, growth
March 29, 2016Manufacturing and Production, Research and Development, Sales and Marketing M&A, MA, Orphan Drugs, cancer drugs
Moody’s Investor Service lowered its growth outlook for the global pharma sector but maintained the mergers and acquisitions in the …
Novo Nordisk breaks ground on new $2 billion production facility in North Carolina
March 29, 2016Manufacturing and Production, Research and Development $2 billion, Clayton, Novo, Novo Nordisk, building, diabetes, nordisk, north carolina, production facility
Novo Nordisk has begun work on a new $2 billion production facility in Clayton, North Carolina, which will produce active …
US FDA issues observations for Natco Pharma’s Indian plants
March 29, 2016Manufacturing and Production, Research and Development, Sales and Marketing
Shares in India-based Natco Pharma (BOM: 524816) dropped on the Bombay Stock Exchange following news the US Food and Drug …
Sanofi names MedImmune chief head of research
March 29, 2016Sanofi has announced the appointment of Yong-Jun Liu as head of research at the French company.Liu, an immunology specialist with …
Portola Pharma stock drops on dismal Phase III trial results for blood-clot drug
March 29, 2016Manufacturing and Production, Research and Development, Sales and Marketing Portola Pharmaceuticals, blood clot drug, drug trial, phase III
Shares in Portola Pharmaceuticals (Nasdaq: PTLA) dropped after the company reported disappointing late-stage trial results for its blood clotting drug. …
FDA issues CRL for Takeda/Lundbeck’s Brintellix
March 29, 2016Manufacturing and Production, Research and Development Lundbeck, Takeda, brintellix
Takeda and Lundbeck have received a complete response letter from the US Food and Drug Administration (FDA) for the supplemental …
US govt demands records of Novartis’ educational events in kickbacks suit
March 29, 2016Business Services, Manufacturing and Production, Sales and Marketing Novartis, US government, legal, regulation
Swiss pharma major Novartis (VTX: NOVN) has said the US lawsuit has exploded with the regulators demanding information for about …
Japanese approval for AZ lung cancer drug
March 29, 2016Manufacturing and Production, Sales and Marketing AstraZeneca, Tagrisso, lung cancer
AstraZeneca’s Tagrisso (osimertinib) has been approved in Japan for the treatment of a specific form of clung cancer. Japanese regulator, …
Mylan launches generic of Valeant’s Ultram in the US
March 29, 2016Manufacturing and Production, Sales and Marketing FDA, Mylan, Valeant, abbreviate new drug application, generic, pain, tramadol, ultram
Mylan (NASDAQ, TASE: MYL) has announced the launch of its generic version of Valeant’s Ultram tablets in the US. The …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
